key: cord-0023315-5e7z3aqy
authors: Donaldson, Gavin C.; Ritchie, Andrew I.; Calverley, Peter M.A.; Vestbo, Jorgen; Fageras, Malin; de la Hoz, Alberto; Bucchioni, Enrica; Compton, Chris H.; Mezzi, Karen; Wedzicha, Jadwiga A.
title: Impact of the UK lockdown on people at risk of COPD
date: 2021-11-22
journal: ERJ Open Res
DOI: 10.1183/23120541.00358-2021
sha: e3f61e622033b87576dd99a66fdf2cfc6c6691ba
doc_id: 23315
cord_uid: 5e7z3aqy

Impact of the UK lockdown on early COPD https://bit.ly/3laMsmi

By telephone, participants were asked about smoking habits, upper respiratory tract infection (URTIs) and lower respiratory tract infections (LRTIs). They were also sent the COPD Assessment Test (CAT), Leicester Cough Questionnaire, Hospital Anxiety and Depression Scale questionnaire, and questions 1 and 2 of the St George's Respiratory Questionnaire (SGRQ) for diagnoses of chronic bronchitis [7, 8] . 27 participants did not return the questionnaires. Statistical comparisons were made by paired t-test or Wilcoxon matched pairs test; comparisons between groups were made by Mann-Whitney and Chi-squared tests as appropriate. Remote telephone visits were approved by a nonsubstantial amendment to the ethics approval (London-Riverside Research Ethics Committee, 16LO2041).

Data were obtained during lockdown between the 16 April and 25 September 2020 from 260 individuals (25 participants in Belfast, 38 in Birmingham, 25 in Edinburgh, 101 in London, 27 in Manchester and 44 in Nottingham). The mean±SD age was 38.1±4.6 years (n=259), 155 (59.6%) were male and the post-bronchodilator FEV 1 at enrolment was 3.81±0.8 L (101±11% of Global Lung Function Initiative predicted). The interval between the two visits was 196 days (interquartile range (IQR) 80-238 days). 187 continued to smoke and 22 had already quit. In those who smoked before and during lockdown, assessed over the 7 days preceding each visit, tobacco consumption (cigarettes per day; Wilcoxon p = 0.587) and rolling tobacco (grams per week; Wilcoxon p = 0.924) was unchanged.

During lockdown, the anxiety component scores increased from 6.7±4.4 to 7.4±4.7) (n = 233; t-test p = 0.010) and depression scores increased from 4.30±3.9 to 5.14±4.1) (n = 233; t-test p<0.001). Anxiety increased in 78 out of 233 and depression in 89 out of 233 participants by ⩾2 units, the minimally important difference in COPD [9] .

Respiratory symptoms improved during lockdown, with CAT scores falling from 9 (IQR 6-15) to 8 (IQR 5-13) (n = 233; Wilcoxon p = 0.008) and the total Leicester Cough Questionnaire score indicating improvement, as it increased from 19.7 (IQR 17.6-20.6) to 20.0 (IQR 18.7-20.8) (n = 204; Wilcoxon p = 0.045).

A comparison of the 40 patients who quit during lockdown with those 187 who smoked at both visits showed no difference prior to lock down in CAT scores (Mann-Whitney p = 0.814) or in the prevalence of chronic as bronchitis defined by the SGRQ (Chi-squared p = 0.607). However, after quitting, CAT scores were lower (5 (IQR 3-13) compared with 9 (IQR 6-13)) in smokers (Mann-Whitney p = 0.0307) and chronic bronchitis less prevalent (four (11.8%) out of 34) than in those who continued to smoke (47 (28.1%) out of 167) (Chi-squared p = 0.045).

The number of URTIs recalled by the participants fell from a median of 1 (IQR 0-2; group mean 1.24) when asked pre-pandemic to a median 1 (IQR 0-1; group mean 0.84) (Wilcoxon p = 0.0002) when asked during lockdown. There was no difference in the number of LRTIs (Wilcoxon p = 0.192) . In summary, during the UK national lockdown and a period of enforced social distancing, there was a significant increase in the proportion of 30-45-year-old smokers who quit smoking despite increased levels of depression and anxiety. It has been reported that depressed individuals are more likely to be nicotine dependent but paradoxically, older depressed adults coupled with health concerns are more motivated to quit [10] . Stress may have enhanced lockdown as an important moment at which to quit. One limitation in our study is the absence of objective measures of nicotine use. However, participants who self-reported that they had quit smoking had a reduced prevalence of chronic bronchitis and lower CAT scores, which suggests they were truthful about their habits. There was also a reduced number of URTIs, again suggestive that participants had fewer social interactions and opportunities for cross-infection.

Our findings suggest that any evaluation of the health response to the pandemic needs to balance deterioration in mental health in specific age groups with improvements in respiratory health. 

Cigarette smoking and infection

How cigarette smoke skews immune responses to promote infection, lung disease and cancer

Covid-19 and smoking: a systematic review of the evidence

Covid-19, smoking, vaping and quitting: a representative population survey in England

Association of the COVID-19 lockdown with smoking, drinking and attempts to quit in England: an analysis of 2019-20 data

panic-puffs-half-of-smokers-are-stress-smoking-more-sincethe-pandemic-started

The St. George's respiratory questionnaire definition of chronic bronchitis may be a better predictor of COPD exacerbations compared with the classic definition

Comparison between an alternative and the classic definition of chronic bronchitis in COPDgene

Anxiety and depression in bronchiectasis: response to pulmonary rehabilitation and minimal clinically important difference of the hospital anxiety and depression scale

Smoking cessation behavior in older adults by race and gender: The role of health problems and psychological distress

National Heart and Lung Institute, Imperial College London, London, UK. 2 Conflict of interest: G.C. Donaldson reports grants from AstraZeneca, and personal fees from AstraZeneca, the American Thoracic Society, FWO Flanders and Novartis, outside the submitted work. A.I. Ritchie has nothing to disclose. P.M.A. Calverley reports grants and personal fees from GlaxoSmithKline, personal fees from AstraZeneca, Boehringer Ingelheim, Phillips Respironics, Novartis, Recipharm and Zambon, and personal fees and nonfinancial support from Boehringer Ingelheim outside the submitted work. J. Vestbo reports personal fees from AstraZeneca and Boehringer Ingelheim, grants from Boehringer Ingelheim, and personal fees from Chiesi, GSK, Novartis and TEVA, outside the submitted work. M. Fageras has nothing to disclose. A. de la Hoz reports a salary from Boehringer Ingelheim International. E. Bucchioni is an employee of Chiesi. C.H. Compton is an employee of and holds shares in GSK. K. Mezzi is a Novartis Pharma AG employee. J.A. Wedzicha reports grants from GSK, meeting expenses only (no personal fees since January 2015) from Novartis, Boehringer Ingelheim and AstraZeneca, and a grant from Chiesi outside the submitted work. Support statement: The study is funded by AstraZeneca, Boehringer Ingelheim, Cheisi, GSK and Novartis. Funding information for this article has been deposited with the Crossref Funder Registry.